BIOVINC, LLC

A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures

BIOVINC, LLC is a business in national institute of allergy and infectious diseases based in SANTA BARBARA, CA, founded in 2014.

Profile

ABSTRACT
Bone fracture is a large medical problem in the US, with 6 million presentations each year, resulting in
very large cost burdens. In addition, the total burden of fractures in the US is growing due to the aging of the
population and increases in osteoporosis. Some of these fractures do not heal properly, largely due to infections
resulting in high additional costs and morbidity in this subset of patients. Also, open fractures, often caused by
trauma, can lead to a very high rate of infection (20-30%), which might result in nonunion or amputation even
with the best of care. Reducing this significant burden to both the quality of life of the patients affected and to
the US public health and health systems is a very significant need. Bisphosphonates (BPs) are a class of
therapeutic compounds used to treat bone resorptive disorders, and accumulate in bone with exceptionally high
affinity, which makes them an excellent moiety for a novel bone targeted drug delivery platform.
BioVinc is a company founded to be a leader in bone related diseases and has an extensive amount of
preliminary data showing the feasibility of using novel bone targeted bisphosphonate conjugated fluoroquinolone
compounds as a treatment for bone fracture healing problems. In this FastTrack SBIR proposal we will move the
BioVinc solution for infected delayed/non-union fracture toward commercial use. Ou

Within the national institute of allergy and infectious diseases space, the company focuses on its core offering rather than a broad product line.

Its base of operations is SANTA BARBARA, CA.

Directory data places it at the SBIR/STTR stage.

Its team size is recorded as 1-10 employees.

Public records show total funding of about $993K.

Website: biovinc.com